All In Biotech

Drug Trial Radar · NCT06767683

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

786

Planned (sponsor's estimate)

Start

Jan 27, 2025

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.

Conditions

  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Idiopathic Hypersomnia

Interventions

  • ALKS 2680, 4mgDrug

    Oral tablet containing 4 mg of ALKS 2680 for once daily administration

  • ALKS 2680, 6mgDrug

    Oral tablet containing 6 mg of ALKS 2680 for once daily administration

  • ALKS 2680, 8mgDrug

    Oral tablet containing 8 mg of ALKS 2680 for once daily administration

  • ALKS 2680, 10mgDrug

    Oral tablet containing 10 mg of ALKS 2680 for once daily administration

  • ALKS 2680, 14mgDrug

    Oral tablet containing 14 mg of ALKS 2680 for once daily administration

  • ALKS 2680, 18mgDrug

    Oral tablet containing 18 mg of ALKS 2680 for once daily administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Up to 248 Weeks

Locations

50 sites in 8 countries. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Cullman, Alabama · Recruiting

  • Alkermes Investigator Site

    Phoenix, Arizona · Recruiting

  • Alkermes Investigational Site

    Little Rock, Arkansas · Recruiting

  • Alkermes Investigational Site

    Los Angeles, California · Recruiting

  • Alkermes Investigator Site

    San Francisco, California · Recruiting

  • Alkermes Investigational Site

    Stanford, California · Recruiting

  • Alkermes Investigational Site

    Boulder, Colorado · Recruiting

  • Alkermes Investigational Site

    Colorado Springs, Colorado · Recruiting

  • Alkermes Investigational Site

    Brandon, Florida · Recruiting

  • Alkermes Investigational Site

    Miami, Florida · Recruiting

  • Alkermes Investigational Site

    Winter Park, Florida · Recruiting

  • Alkermes Investigational Site

    Atlanta, Georgia · Recruiting

  • Alkermes Investigational Site

    Macon, Georgia · Recruiting

  • Alkermes Investigational Site

    Stockbridge, Georgia · Recruiting

  • Alkermes Investigational Site

    Peoria, Illinois · Recruiting

  • Alkermes Investigational Site

    Kansas City, Kansas · Recruiting

  • Alkermes Investigational Site

    Lansing, Michigan · Recruiting

  • Alkermes Investigational Site

    Sterling Heights, Michigan · Recruiting

  • Alkermes Investigational Site

    Lincoln, Nebraska · Recruiting

  • Alkermes Investigational Site

    Middletown, New Jersey · Terminated

  • Alkermes Investigational Site

    Denver, North Carolina · Recruiting

  • Alkermes Investigational Site

    Huntersville, North Carolina · Recruiting

  • Alkermes Investigational Site

    Canton, Ohio · Recruiting

  • Alkermes Investigational Site

    Cincinnati, Ohio · Recruiting

  • Alkermes Investigational Site

    Cincinnati, Ohio · Recruiting

  • Alkermes Investigational Site

    Dublin, Ohio · Recruiting

  • Alkermes Investigational Site

    Abington, Pennsylvania · Recruiting

  • Alkermes Investigational Site

    Wyomissing, Pennsylvania · Recruiting

  • Alkermes Investigational Site

    Columbia, South Carolina · Recruiting

  • Alkermes Investigational Site

    Austin, Texas · Recruiting

  • Alkermes Investigational Site

    Dallas, Texas · Recruiting

  • Alkermes Investigational Site

    San Antonio, Texas · Recruiting

  • Alkermes Investigational Site

    Sugar Land, Texas · Recruiting

  • Alkermes Investigational Site

    Madison, Wisconsin · Recruiting

  • Alkermes Investigational Site

    Sydney, New South Wales, Australia · Recruiting

  • Alkermes Investigational Site

    Bedford Park, South Australia, Australia · Recruiting

  • Alkermes Investigational Site

    Clayton, Victoria, Australia · Recruiting

  • Alkermes Investigational Site

    Alken, Belgium · Recruiting

  • Alkermes Investigational Site

    Namur, Belgium · Recruiting

  • Alkermes Investigational Site

    Bruges, Brugge, Belgium · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.